Erasca, Inc. Stock News

Erasca (ERAS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

FSM, LPX and ERAS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 23, 2024.

CQP, AL, FSM, ERAS and QUAD have been added to the Zacks Rank #1 (Strong Buy) List on April 23, 2024.

Erasca, Inc. (ERAS) R&D Update Call and Q4 2023 Earnings Call Transcript

SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for

Although extremely risky, penny stocks can provide tactical value to a portfolio. The risk of losing it all is very real.

Penny stocks, defined as stocks trading under $5 per share, are known for their volatility. Even small pieces of news or unconfirmed rumors can send some penny stocks swinging wildly up or down in pri

Penny stocks – the cheap stocks trading under $5 per share, offer investors massive upside potential alongside higher risk. Since even incremental price moves translate into huge percentage gains in

SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for p

SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for

Two new sample Breakout Stocks for Week 35 curated by the MDA model for a 10% short-term upside along with a Dow pick. The Momentum Gauges, S&P 500 Gauges, and Weekly Gauges all continue negative afte

Two new Breakout Stocks for Week 33 curated by the MDA model for 10% short-term upside along with one Dow pick. Last week two of four picks gained over the 10% mark in less than a week with peak gains

Triplet of ERAS-007 100 mg BID-QW + encorafenib + cetuximab (EC) in EC-naïve patients with metastatic BRAF V600E-mutated colorectal cancer (CRC) showed a 40% (2/5) response rate; continued evaluation

Fintel reports that on May 16, 2023, Goldman Sachs maintained coverage of Erasca (NASDAQ:ERAS) with a Buy recommendation.

Erasca, Inc. is a clinical-stage biopharmaceutical developer of therapies for patients with RAS/MAPK pathway-driven cancers. Shares were dragged down sharply by headwinds from the Fed's hawkish stance